Evidence map›Paper›PMID 35268671›Full record

ArticleMolecules (Basel, Switzerland)2022

RETRACTED: Curcumin-Injected

Shaymaa Mahmoud, Sobhy Hassab El-Nabi, Asmaa Hawash, Hesham R El-Seedi, Shaden A M Khalifa, Sami Ullah, Abdullah G Al-Sehemi, Islam M El-Garawani

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. RETRACTED: Mahmoud et al. Curcumin-InjectedMolecules (Basel, Switzerland) · 2025
    Article
  2. Review
  3. Isolation of Peptide Inhibiting SGC-7901 Cell Proliferation fromInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Shaymaa MahmoudDepartment of Zoology, Faculty of Science, Menoufia University, Menoufia 32511, Egypt.ORCID 0000-0001-5497-6429
Sobhy Hassab El-NabiDepartment of Zoology, Faculty of Science, Menoufia University, Menoufia 32511, Egypt.
Asmaa HawashDepartment of Zoology, Faculty of Science, Menoufia University, Menoufia 32511, Egypt.
Hesham R El-SeediDepartment of Chemistry, Faculty of Science, Menoufia University, Menoufia 32511, Egypt.
Shaden A M KhalifaDepartment of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, S-106 91 Stockholm, Sweden.
Sami UllahResearch Center for Advanced Materials Science (RCAMS), King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia.
Abdullah G Al-SehemiResearch Center for Advanced Materials Science (RCAMS), King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia.ORCID 0000-0002-6793-3038
Islam M El-GarawaniDepartment of Zoology, Faculty of Science, Menoufia University, Menoufia 32511, Egypt.ORCID 0000-0002-7241-4910
Menoufia University · EGKing Khalid University · SAJiangsu University · CNSinai University · EGStockholm University · SE

Funding

King Khalid University through Research Center for Advanced Materials Science (RCAMS) RCAMS/KKU//008/21
6 · The paper itself

Abstract

Over recent decades, much attention has been given to imply the natural products in cancer therapy alone or in combination with other established procedures. Insects have a rich history in traditional medicine across the globe, which holds promise for the future of natural product drug discovery. Cecropins, peptides produced by insects, are components of a defense system against infections and are well known to exert antimicrobial and antitumor capabilities. The present study aimed to investigate, for the first time, the role of curcumin in enhancing the anticancer effect of Musca domestica larval hemolymph. Third larval instars of M. domestica were injected with curcumin and the hemolymph was picked at 4, 8, and 24 h post-curcumin injection. M. domestica cecropin A (MdCecA) was evaluated in control and injected larval hemolymphs. The cytotoxicity on breast cancer cell lines (MCF-7) and normal Vero cells was assessed to be comparable to control larval hemolymph. Curcumin-injected larval hemolymphs exhibited significant cytotoxicity with respect to the uninjected ones against MCF-7; however, Vero cells showed no cytotoxicity. The IC50 was 106 ± 2.9 and 388 ± 9.2 μg/mL for the hemolymphs of injected larvae at 4 and 8 h, respectively, while the control larval hemolymph revealed the IC50 of >500 μg/mL. For mechanistic anticancer evaluation, concentrations of 30, 60, and 100 μg/mL of curcumin-injected larval hemolymphs were examined. A significant G2/M cell cycle arrest was observed, confirming the anti-proliferative properties of hemolymphs over the tested concentrations. The MdCecA transcripts were significantly (p < 0.05) upregulated at 4 and 8 h post-injection, while a significant downregulation was observed after 24 h. Cecropin quantification by LC−MS revealed that MdCecA peptides have the highest expression in the hemolymph of the treated larvae at 8 h relative to the control group. The upregulation of cecropin expression at mRNA and protein levels may be attributed to the curcumin stimulation and linked to the increased cytotoxicity toward the cancer cell line. In conclusion, the results suggest that the apoptotic and anti-proliferative effects of M. domestica hemolymph on MCF-7 cells following the curcumin injection can be used as a natural candidate in future pharmaceutical industries.

Indexed as

Antineoplastic AgentsCecropinsCurcuminHemolymphHousefliesLarvaAnimalsApoptosisCell ProliferationChlorocebus aethiopsHumansMCF-7 CellsUp-RegulationVero CellsAntineoplastic AgentsCecropinsCurcuminapoptosiscecropincurcumincytotoxicityhemolymphMCF-7M. domestica larva

Identifiers

PMID35268671
PMCPMC8911634
OpenAlexW4214598146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.